2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险 - Suppr

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

作者信息

Mach François, Baigent Colin, Catapano Alberico L, Koskinas Konstantinos C, Casula Manuela, Badimon Lina, Chapman M John, De Backer Guy G, Delgado Victoria, Ference Brian A, Graham Ian M, Halliday Alison, Landmesser Ulf, Mihaylova Borislava, Pedersen Terje R, Riccardi Gabriele, Richter Dimitrios J, Sabatine Marc S, Taskinen Marja-Riitta, Tokgozoglu Lale, Wiklund Olov

出版信息

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

DOI:10.1093/eurheartj/ehz455

PMID:31504418

Abstract

摘要

相似文献

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012.

Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?

Eur Heart J. 2020 Jun 21;41(24):2332. doi: 10.1093/eurheartj/ehz940.

The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.

Atherosclerosis. 2020 Jan;292:231-233. doi: 10.1016/j.atherosclerosis.2019.11.009. Epub 2019 Nov 14.

A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?

Eur Heart J. 2020 Jun 21;41(24):2331. doi: 10.1093/eurheartj/ehaa005.

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Atherosclerosis. 2011 Jul;217(1):3-46. doi: 10.1016/j.atherosclerosis.2011.06.028.

New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?

Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):724-7. doi: 10.1177/1741826711418946.

引用本文的文献

Prescription of lipid-lowering drugs and their association with hospitalization for ST-elevation myocardial infarction (STEMI) in Germany in 2010-2022.

Clin Res Cardiol. 2025 Sep 8. doi: 10.1007/s00392-025-02739-9.

European survey on metabolic and cardiovascular risk in Cushing syndrome.

J Endocrinol Invest. 2025 Sep 6. doi: 10.1007/s40618-025-02663-9.

Divergence in Estimated Risks and Actual Rates of Atherosclerotic Cardiovascular Events and their Management in a Longitudinal Cohort of Patients with Dermatomyositis with Skin Involvement.

JID Innov. 2025 Jul 7;5(6):100399. doi: 10.1016/j.xjidi.2025.100399. eCollection 2025 Nov.

The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report.

Eur Heart J Case Rep. 2025 Aug 9;9(9):ytaf389. doi: 10.1093/ehjcr/ytaf389. eCollection 2025 Sep.

Comparison of Artificial Intelligence Models and Human Experts in Managing Dyslipidemia: Assessment of Adherence to Clinical Guidelines.

Cureus. 2025 Aug 31;17(8):e91363. doi: 10.7759/cureus.91363. eCollection 2025 Aug.

The Gulliver syndrome: a conceptual framework to address therapeutic inertia in patients with borderline cardiovascular risk profiles.

Front Cardiovasc Med. 2025 Aug 14;12:1652447. doi: 10.3389/fcvm.2025.1652447. eCollection 2025.

Impact of severe dyslipidemia on renal function: A cross-sectional study.

Medicine (Baltimore). 2025 Aug 29;104(35):e44131. doi: 10.1097/MD.0000000000044131.

From guidelines to practice: LDL-C achievement in very high cardiovascular risk patients - analysis of the EDHIPO MARCA registry.

Lipids Health Dis. 2025 Sep 2;24(1):275. doi: 10.1186/s12944-025-02657-9.

Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.

Trials. 2025 Sep 1;26(1):326. doi: 10.1186/s13063-025-08943-2.

Association between dynamic changes in the triglyceride-glucose index and prognosis in patients with acute ST-segment elevation myocardial infarction.

Cardiovasc Diabetol. 2025 Sep 1;24(1):357. doi: 10.1186/s12933-025-02858-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献